Topic: Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS)

Aug 2022 | Assessment

Interventions of Interest: AMX0035 (RELYVRIO™, Amylyx Pharmaceuticals, Inc.) oral edaravone (Mitsubishi Tanabe Pharma Development America, Inc.) The majority of independent appraisal committee voted that the evidence is adequate to demonstrate that both AMX0035 and oral edaravone (in population narrower than its label) provide a net health benefit compared to standard of care. They also determined […]